Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

The Gates Foundation has announced an investment of $2.5bn to 2030, dedicated to expediting R&D with a focus on improving women's health.

APAC-based biotech companies in Singapore, South Korea and Japan may offer investors the stability and innovation they are searching for.

England has launched a world-first gonorrhoea vaccination programme that will potentially help avert up to 100,000 cases of the disease and save millions of NHS funding.

The Saudi Food and Drug Authority (SFDA) has approved Agios' Pyrukynd (mitapivat) for adults with alpha or beta-thalassemia.

For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU.

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Arrowhead's subsidiary Visirna has entered an agreement with Sanofi for plozasiran, a potential treatment for hypertriglyceridemia.

Sandoz will acquire Just – Evotec Biologics’ biosimilar development and manufacturing plant in Toulouse for $300m.

Analysis by GlobalData characterises an uncertain pharma landscape, though big pharma CEOs allay investor concern.